63E Stock Overview
Onward Medical N.V., a medical technology company, develops implantable neuro-stimulation Systems and non-invasive systems for electrical stimulation of specific areas of the spinal cord.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Onward Medical N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €4.51 |
| 52 Week High | €6.54 |
| 52 Week Low | €2.00 |
| Beta | 0.79 |
| 1 Month Change | -18.59% |
| 3 Month Change | -19.75% |
| 1 Year Change | -2.59% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -62.73% |
Recent News & Updates
Recent updates
Shareholder Returns
| 63E | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -1.3% | -0.4% | 1.9% |
| 1Y | -2.6% | -6.0% | 5.9% |
Return vs Industry: 63E exceeded the German Medical Equipment industry which returned -6.1% over the past year.
Return vs Market: 63E underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 63E volatility | |
|---|---|
| 63E Average Weekly Movement | 16.7% |
| Medical Equipment Industry Average Movement | 4.6% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 63E's share price has been volatile over the past 3 months.
Volatility Over Time: 63E's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 96 | Dave Marver | www.onwd.com |
Onward Medical N.V., a medical technology company, develops implantable neuro-stimulation Systems and non-invasive systems for electrical stimulation of specific areas of the spinal cord. The company engages in developing ARCEX, a transcutaneous system designed to improve upper extremity strength, function, and other symptoms in people with spinal cord injury (SCI); ARCIM, a minimally invasive implantable system to address blood pressure instability and other symptoms in people with SCI; and ARCBCI, which adds an implantable bran-computer interface to the ARCIM to restore thought-driven movement of the upper and lower limbs. Onward Medical N.V. was founded in 2014 and is headquartered in Eindhoven, Netherlands.
Onward Medical N.V. Fundamentals Summary
| 63E fundamental statistics | |
|---|---|
| Market cap | €163.79m |
| Earnings (TTM) | -€36.20m |
| Revenue (TTM) | €500.00k |
327.6x
P/S Ratio-4.5x
P/E RatioIs 63E overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 63E income statement (TTM) | |
|---|---|
| Revenue | €500.00k |
| Cost of Revenue | €3.00m |
| Gross Profit | -€2.50m |
| Other Expenses | €33.70m |
| Earnings | -€36.20m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.05 |
| Gross Margin | -500.00% |
| Net Profit Margin | -7,240.00% |
| Debt/Equity Ratio | 46.3% |
How did 63E perform over the long term?
See historical performance and comparison